ArQule News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

08.04.18	An Ear To The Pharma: 9 Stocks To Watch This Week (SELB, AGLE, BPMC, MNOV…) (RTTNews)
27.03.18	EKSO Leaps, FDA Nod For DRIO, CRVS Up 38% This Month, VTL To Report Data In Sep. (RTTNews)
22.03.18	GERN Turning Heads, ARQL To Present Data In Apr., Mark Your Calendar For PTN (RTTNews)
20.03.18	ArQule to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018 (Businesswire)
16.03.18	DXR On Fire, IONS Ups Stake In AKCA, HAIR Grows, FLKS To Report Data This Month (RTTNews)
15.03.18	ArQule to Present Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting (Businesswire)
05.03.18	EARNINGS SUMMARY: Details of ArQule Inc. Q4 Earnings Report (RTTNews)
05.03.18	ArQule Reports Fourth Quarter and Full Year 2017 Financial Results (Businesswire)
05.03.18	ArQule to Present at the 30th Annual Roth Conference on March 12, 2018 (Businesswire)
20.02.18	ArQule To Report Fourth Quarter 2017 Financial Results On March 5, 2018 (Businesswire)
08.02.18	ArQule to Present at The Leerink Partners 7th Annual Global Healthcare Conference on February 15, 2018 (Businesswire)
07.02.18	Roivant Sciences and ArQule Enter into License Agreement for Derazantinib in China (Businesswire)
21.11.17	ArQule Announces Dosing In Registrational Trial Of FGFR Inhibitor Derazantinib (RTTNews)
21.11.17	ArQule Announces Dosing in a Registrational Trial of FGFR Inhibitor, Derazantinib, for Treatment of Intrahepatic Cholangiocarcinoma (Businesswire)
09.11.17	EARNINGS SUMMARY: Details of ArQule Inc. Q3 Earnings Report (RTTNews)
09.11.17	ArQule Reports Third Quarter 2017 Financial Results (Businesswire)
08.11.17	ArQule Announces $9.5 Million Private Placement of Preferred Stock (Businesswire)
01.11.17	ArQule Says FDA Grants Rare Pediatric Disease Designation To Miransertib (RTTNews)
01.11.17	FDA Grants Rare Pediatric Disease Designation to ArQule’s Miransertib (ARQ 092) for the Treatment of Proteus Syndrome (Businesswire)
04.08.17	EARNINGS SUMMARY: Details of ArQule Inc. Q2 Earnings Report (RTTNews)
11.07.17	ArQule: First Patient Dosed In ARQ 531 Phase 1 Trial For B-cell Malignancies (RTTNews)
26.06.17	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating ArQule, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors (PR Newswire)
03.05.17	EARNINGS SUMMARY: Details of ArQule Inc. Q1 Earnings Report (RTTNews)
28.03.17	FDA Nod For TSRO, Déjà Vu For ARQL, FOMX Plunges On Trial Data, SELB Abuzz (RTTNews)
07.03.17	EARNINGS SUMMARY: Details of ArQule Inc. Q4 Earnings Report (RTTNews)
17.02.17	Daiichi Sankyo and ArQule Announce the Completion of the METIV-HCC Phase 3 Study of Tivantinib in Second-Line Treatment of MET-Overexpressing Hepatocellular Carcinoma (PR Newswire)
02.02.17	Gainers & Losers Of The Day: PULM, ETRM, SMMT, BVX, ARQL... (RTTNews)
07.11.16	ArQule Q3 Net Loss Widens (RTTNews)
07.11.16	EARNINGS SUMMARY: Details of ArQule Inc. Q3 Earnings Report (RTTNews)
03.08.16	EARNINGS SUMMARY: Details of ArQule Inc. Q2 Earnings Report (RTTNews)
30.06.16	ArQule Presents Anti-Cancer Activity For Its ARQ 087 In Rare Liver Cancer (RTTNews)
23.06.16	ArQule To Present Data From Phase1/2 Trial Of ARQ 087 (RTTNews)
04.05.16	ArQule Issues 2016 Guidance - Quick Facts (RTTNews)
04.05.16	EARNINGS SUMMARY: Details of ArQule Inc. Q1 Earnings Report (RTTNews)
22.03.16	ArQule Announces Continuation Of METIV-HCC Phase 3 Study Of Tivantinib (RTTNews)
29.02.16	EARNINGS SUMMARY: Details of ArQule Inc. Q4 Earnings Report (RTTNews)
15.12.15	ArQule Reports Orphan Drug Status For ARQ 087 In Cholangiocarcinoma (RTTNews)
17.11.15	ArQule Gets Orphan Drug Designation For ARQ 092 In Proteus Syndrome (RTTNews)
04.11.15	EARNINGS SUMMARY: Details of ArQule Inc. Q3 Earnings Report (RTTNews)
05.08.15	ArQule Q2 Loss Narrows, Revenues Rise - Quick Facts (RTTNews)
06.07.15	ArQule Announces Interim Phase 2 Study Results For Tivantinib - Quick Facts (RTTNews)
04.03.15	ArQule Q4 Loss Narrows; Issues FY15 Outlook - Quick Facts (RTTNews)
10.11.14	ArQule Reports Positive Top-Line Results Of Phase 2 Trial Of Tivantinib (RTTNews)
04.02.14	ArQule Announces Commencement Of Late-stage Trial With Tivantinib In Japan (RTTNews)
16.01.14	After-market Movers For Jan 16 (INTC, COF, RDEN, SSNI, ARQL) (RTTNews)
04.02.10	ArQule Announces Initiation of Clinical Programs with ARQ 197 in Germ Cell Tumors and Colorectal Cancer (Businesswire)
05.03.09	ArQule Expands Clinical Program With ARQ 197, c-Met Inhibitor (Businesswire)
04.08.08	ArQule, Inc. to Report Second Quarter 2008 Financial Results on Monday, August 11, 2008 (Businesswire)
20.06.08	ArQule Announces Appointment of Brian Schwartz as Chief Medical Officer (Businesswire)
12.05.08	ArQule Reports First Quarter 2008 Financial Results (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Swisscom	532.50	3.70 %	K V
Nestle	90.66	0.96 %	K V
Lonza Grp	537.00	0.94 %	K V
Givaudan	3’860.00	0.92 %	K V
Novartis	97.30	0.50 %	K V
CieFinRichemont	144.55	-6.32 %	K V
Part Grp Hldg	1’164.00	-6.58 %	K V
UBS Group	24.55	-8.33 %	K V
Kuehne+Nagel Int	185.50	-8.49 %	K V
Logitech Intl	63.00	-16.53 %	K V

ArQule Aktie VALOR 519003 / ISIN US04269E1073

Nachrichten zu ArQule Inc.

Aktien Top/Flop

Meistgelesene Nachrichten